Medtronic: A Healthcare Giant with 48 Years of Dividend Increases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 22 2026
0mins
Should l Buy MDT?
Source: Fool
- Dividend Increase Record: Medtronic has raised its dividend for 48 consecutive years, with a current yield of nearly 3%, significantly higher than the average of S&P 500 stocks, demonstrating a strong commitment to shareholder returns.
- Stable Revenue Sources: Since 2000, Medtronic has only seen revenue declines in 2020 and 2023, due to the COVID-19 pandemic and supply chain issues, indicating its resilience in the medical device sector.
- Diversified Business Structure: Medtronic's four business units—cardiovascular, medical-surgical, neuroscience, and diabetes—generate strong revenue streams, although the diabetes unit is set to be spun off, the overall business remains highly competitive.
- FDA Approval for New Technology: Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for specific urologic procedures, signaling future growth potential and expected performance that could surpass the S&P 500.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 86.060
Low
102.00
Averages
111.76
High
120.00
Current: 86.060
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anteris Aims to Reshape $10B Heart Market with Innovative Valve
- Market Opportunity Identification: Anteris Technologies is developing a new TAVR valve through its DurAVR program to meet the needs of younger patients requiring heart valve replacements, with the market projected to reach $10 billion by 2028, indicating significant growth potential.
- Design Innovation: Unlike existing valves, DurAVR features a single-piece molded design combined with a balloon-expandable delivery system, aiming to provide superior hemodynamic performance and address the trade-off between ease of use and performance seen in traditional valves.
- Clinical Trial Progress: Anteris has treated over 130 patients in early studies, demonstrating favorable hemodynamic performance with low pressure gradients and minimal prosthesis-patient mismatch, with the next phase being the PARADIGM pivotal trial enrolling around 1,000 patients for comparative analysis.
- Strategic Investment Support: In early 2026, Anteris completed a $320 million capital raise, including a $90 million strategic investment from Medtronic, validating the technology and market opportunity despite Medtronic being a competitor.
See More
Market Watch: Corporate Dynamics and Analysis
- Nike's Disappointing Performance: Despite beating revenue and earnings expectations, Nike issued weak guidance due to inventory issues and a slowdown in North American growth, prompting downgrades from Goldman, JPMorgan, and Bank of America, reflecting market concerns about its future performance.
- RH's Poor Earnings Report: Luxury home furnishings maker RH fell short on key metrics in its fourth quarter, and its current quarter guidance was also weak, impacted by tariffs and a sluggish housing market, leading to an 18% drop in shares, although its full-year cash flow guidance improved, the overall outlook remains bleak.
- Arm's Price Target Increase: Wells Fargo raised Arm's price target from $165 to $175, with analysts optimistic about Arm's entry into the data center CPU market with its first in-house silicon offering, reiterating a buy rating, indicating strong market confidence in its competition against Intel and AMD.
- Boeing Stock Rating Upgrade: Wells Fargo upgraded Boeing's stock to buy with a price target of $250, implying over 25% upside from yesterday's close, as analysts favor Boeing's free cash flow recovery and overall turnaround under CEO Kelly Ortberg, suggesting potential returns for investors.
See More
MiniMed Shares Rise as Wall Street Sees Bullish Outlook Post-IPO
- Positive Market Outlook: MiniMed (MNMD) shares rose for the first time post-IPO quiet period, despite a ~20% drop since its debut, as analysts express optimism about its future market potential.
- Large Market Size: Wells Fargo issued an Overweight rating, highlighting an $18B market for automated insulin delivery systems with only 7% penetration, indicating significant growth opportunities ahead.
- International Advantage: With operations in ~80 countries and ~70% of revenue generated internationally, analysts believe MiniMed is well-positioned to benefit from expanding global market penetration, further solidifying its market position.
- Significant Competitive Edge: Analysts noted that MiniMed's partnership with Abbott (ABT) starting in CY26 will materially enhance its continuous glucose monitoring systems, providing a key competitive advantage, although some analysts raised concerns about product form factor and usability.
See More
Analysis of FNDF ETF's 52-Week Price Range
- Price Range Analysis: FNDF ETF's 52-week low is $31.915 per share and high is $52.935, with the latest trade at $47.68, indicating relative stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market dynamics.
See More
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Medtronic's Robot-Assisted Surgical System Approved by FDA
- FDA Approval: Medtronic's Stealth AXiS robot-assisted surgical system has received FDA approval for cranial and ENT procedures, marking a significant advancement in the company's medical robotics portfolio.
- Technology Integration: The system integrates preoperative planning, surgical navigation, and robotics, based on technologies from Mazor Robotics, which Medtronic acquired for $1.6 billion in 2019, enhancing surgeon workflows and procedural efficiency.
- Market Outlook: Having received FDA clearance for spine procedures last month, the expansion to cranial and ENT applications is expected to further strengthen Medtronic's competitive position in the robotic surgery market.
- Expert Commentary: Vijay Ramakrishnan, a professor at Indiana University School of Medicine, highlighted that the system enhances surgeon confidence and efficiency through innovative technologies, potentially transforming operating room workflows.
See More
Anteris Aims to Reshape $10B Heart Market with Innovative Valve
- Market Opportunity Identification: Anteris Technologies is developing a new TAVR valve through its DurAVR program to meet the needs of younger patients requiring heart valve replacements, with the market projected to reach $10 billion by 2028, indicating significant growth potential.
- Design Innovation: Unlike existing valves, DurAVR features a single-piece molded design combined with a balloon-expandable delivery system, aiming to provide superior hemodynamic performance and address the trade-off between ease of use and performance seen in traditional valves.
- Clinical Trial Progress: Anteris has treated over 130 patients in early studies, demonstrating favorable hemodynamic performance with low pressure gradients and minimal prosthesis-patient mismatch, with the next phase being the PARADIGM pivotal trial enrolling around 1,000 patients for comparative analysis.
- Strategic Investment Support: In early 2026, Anteris completed a $320 million capital raise, including a $90 million strategic investment from Medtronic, validating the technology and market opportunity despite Medtronic being a competitor.
See More
Market Watch: Corporate Dynamics and Analysis
- Nike's Disappointing Performance: Despite beating revenue and earnings expectations, Nike issued weak guidance due to inventory issues and a slowdown in North American growth, prompting downgrades from Goldman, JPMorgan, and Bank of America, reflecting market concerns about its future performance.
- RH's Poor Earnings Report: Luxury home furnishings maker RH fell short on key metrics in its fourth quarter, and its current quarter guidance was also weak, impacted by tariffs and a sluggish housing market, leading to an 18% drop in shares, although its full-year cash flow guidance improved, the overall outlook remains bleak.
- Arm's Price Target Increase: Wells Fargo raised Arm's price target from $165 to $175, with analysts optimistic about Arm's entry into the data center CPU market with its first in-house silicon offering, reiterating a buy rating, indicating strong market confidence in its competition against Intel and AMD.
- Boeing Stock Rating Upgrade: Wells Fargo upgraded Boeing's stock to buy with a price target of $250, implying over 25% upside from yesterday's close, as analysts favor Boeing's free cash flow recovery and overall turnaround under CEO Kelly Ortberg, suggesting potential returns for investors.
See More
MiniMed Shares Rise as Wall Street Sees Bullish Outlook Post-IPO
- Positive Market Outlook: MiniMed (MNMD) shares rose for the first time post-IPO quiet period, despite a ~20% drop since its debut, as analysts express optimism about its future market potential.
- Large Market Size: Wells Fargo issued an Overweight rating, highlighting an $18B market for automated insulin delivery systems with only 7% penetration, indicating significant growth opportunities ahead.
- International Advantage: With operations in ~80 countries and ~70% of revenue generated internationally, analysts believe MiniMed is well-positioned to benefit from expanding global market penetration, further solidifying its market position.
- Significant Competitive Edge: Analysts noted that MiniMed's partnership with Abbott (ABT) starting in CY26 will materially enhance its continuous glucose monitoring systems, providing a key competitive advantage, although some analysts raised concerns about product form factor and usability.
See More
Analysis of FNDF ETF's 52-Week Price Range
- Price Range Analysis: FNDF ETF's 52-week low is $31.915 per share and high is $52.935, with the latest trade at $47.68, indicating relative stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market dynamics.
See More
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Medtronic's Robot-Assisted Surgical System Approved by FDA
- FDA Approval: Medtronic's Stealth AXiS robot-assisted surgical system has received FDA approval for cranial and ENT procedures, marking a significant advancement in the company's medical robotics portfolio.
- Technology Integration: The system integrates preoperative planning, surgical navigation, and robotics, based on technologies from Mazor Robotics, which Medtronic acquired for $1.6 billion in 2019, enhancing surgeon workflows and procedural efficiency.
- Market Outlook: Having received FDA clearance for spine procedures last month, the expansion to cranial and ENT applications is expected to further strengthen Medtronic's competitive position in the robotic surgery market.
- Expert Commentary: Vijay Ramakrishnan, a professor at Indiana University School of Medicine, highlighted that the system enhances surgeon confidence and efficiency through innovative technologies, potentially transforming operating room workflows.
See More
